The FDA has approved Takeda Pharmaceutical's Ninlaro, a treatment for multiple myeloma that the Japanese company hopes can get established before its blockbuster Velcade loses patent protection.
Takeda Pharmaceutical's top cancer prospect won a speedy FDA approval, wading into a crowded market for multiple myeloma treatments with hopes of duplicating the success of Velcade.
Takeda has 900 reps behind Orexigen's Contrave--but is that investment worth it? Maybe not, RBC Capital Markets' Simos Simeonidis suggested recently in a note to investors. Vivus' Qsymia--with just 50 reps supporting the product--hauled in $14 million in Q3 revenue, compared with just $12.8 million for Contrave.
Nine hundred sales reps are out in the field promoting Orexigen's obesity med Contrave, thanks to the company's marketing partner, Takeda. But for what?
Takeda wants to join the likes of India's Hilleman Labs and Serum Institute and grab a piece of the low-cost vaccine pie. The Japanese pharma closed a €3 million ($3.3 million) equity investment in Belgium-based Univercell to use the latter's technology with vaccines in Takeda's pipeline to produce affordable vaccines for developing countries.
Drug R&D is a tough business. The odds are almost always against success, and the price to be paid for being wrong is cruelly high. That said, it did seem a little harder than usual this year to...
Takeda is settling the score with two plaintiffs over allegedly hiding cancer risks linked to its diabetes drug Actos, almost a month after the company announced that it would complete a settlement program that would resolve most of its pending litigation for similar claims over the med.
India's Pune-based Serum Institute is seeking in-country fast-track approval for a biologic drug candidate to treat all four strains of dengue, the Times of India reported, with the news coming amid speculation over an equity offering by the company and a massive virus outbreak in India.
On Monday, Takeda announced its participation in WIPO Re:Search, a consortium to accelerate research and development of new drugs, vaccines and diagnostics for malaria and tuberculosis.
A month ago it appeared like Takeda might not get enough takers to move forward with its sweeping $2.3 billion offer to settle thousands of claims over the cancer risks of diabetes drug Actos. But over the weekend, the Japanese drugmaker said it had raised the offer by $100 million if certain conditions are hit and now has enough on board to trigger the $2.3 billion settlement.